ExCellThera announces clinical data to be presented at the American Society of Hematology 2019 annual meeting

ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that data from a Phase I/II clinical trial using its lead technology, ECT-001, will be presented at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.

NewsGuest UserDecember 5, 2019ExCellThera, Hematology, ECT-001